リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis

Kato, Konami Hatayama Yuki 下廣 寿 Ichikawa, Hitomi 福田 哲也 鳥取大学 DOI:10.33160/yam.2022.08.013

2022.08.29

概要

Background
Clot waveform analysis (CWA) based on activated partial thromboplastin time (APTT) is a useful assay for hemostasis. However, the effects of activators and phospholipid conditions on CWA have not been adequately investigated. Therefore, we characterized CWA using four different APTT reagents.

Methods
We used 39 archived plasma samples from patients with hemophilia A (HA), 16 samples from patients with HA under emicizumab treatment, and 10 samples from healthy individuals for CWA with four different types of APTT reagents (reagents A, B, C, and D). We then compared Ad|min1|, Ad|min2|, and Ad|max2| from the CWA, which reflect the maximum velocity, maximum acceleration, and maximum decel- eration, respectively, among the four reagents.

Results
Similar clot waveform shapes were observed for each reagent in the healthy donor group, HA group, and HA under emicizumab group, and the waveform was different for each target group. Significant changes were found in clotting time (CT) (s), Ad|min1| (%/s), Ad|min2| (%/s2), and Ad|max2| (%/s2). The waveform pattern for the coagulation reaction by reagent D, comprising silica and synthetic phospholipids, was the fastest among the reagents examined. Further, the difference in Ad|min1| (%/s) and Ad|min2| (%/s2) was larger than that in CT depending on the reagent used(s), indicating that the measured value of CWA was affected by the reagent composition.

Conclusion
Our results showed a significant differ- ence among reagents with varying composition and concentration; this was found to affect the parameters obtained from CWA. Thus, the differences between reagents hinder standardization of quantitative evalu-ation using these parameters; further, this highlights the necessity of understanding the characteristics of APTT reagents and determining the reference range in individual facilities.

Key words
activated partial thromboplastin time; clot waveform; emicizumab; hemophilia A

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1 Sevenet PO, Depasse F. Clot waveform analysis: where do we stand in 2017? Int J Lab Hematol. 2017;39:561-8. DOI: 10.1111/ijlh.12724, PMID: 28876509

2 Lancé MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J. 2015;13:1. DOI: 10.1186/1477- 9560-13-1, PMID: 25937820

3 Levi M, Toh CH, Thachil J, Watson HG; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagula- tion. Br J Haematol. 2009;145:24-33. DOI: 10.1111/j.1365- 2141.2009.07600.x, PMID: 19222477

4 Wada H, Matsumoto T, Ohishi K, Shiraki K, Shimaoka M. Update on the clot waveform analysis. Clin Appl Thromb Hemost. 2020;26. DOI: 10.1177/1076029620912027, PMID: 32862666

5 Shima M, Thachil J, Nair SC, Srivastava A; Scientific and Standardization Committee. Towards standardization of clot waveform analysis and recommendations for its clinical ap- plications. J Thromb Haemost. 2013;11:1417-20. DOI: 10.1111/ jth.12287, PMID: 23648068

6 Wada H. APTT waveform. Nihon Kessen Shiketsu Gakkai shi. 2018;29:413-20. DOI: 10.2491/jjsth.29.413

7 Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IX a/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16:1078-88. DOI: 10.1111/jth.14022, PMID: 29645406

8 Yamazaki S, Suzuki N, Goto H, Takayama S. Current condi- tions of activated partial thromboplastin time and a strategy for standardization. Int J Anal Bio-sci. 2009;32:365-70.

9 Cheong MA, Tan CW, Wong WH, Kong MC, See E, Yeang SH, et al. A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin. Hematology. 2022;27:337-42. DOI: 10.1080/16078454.2022.2043573,PMID: 35255239

10 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Trans- plant. 2013;48:452-8. DOI: 10.1038/bmt.2012.244, PMID: 23208313

11 Toh CH, Giles AR. Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). Clin Lab Haematol. 2002;24:321-7. DOI: 10.1046/j.1365-2257.2002.00457.x,PMID: 12452811

12 Matsumoto T, Nogami K, Shima M. A combined approach using global coagulation assays quickly differentiates coagu- lation disorders with prolonged aPTT and low levels of FVIII activity. Int J Hematol. 2017;105:174-83. DOI: 10.1007/s12185- 016-2108-x, PMID: 27730530

13 Matsumoto T, Wada H, Fujimoto N, Toyoda J, Abe Y, Ohishi K, et al. An evaluation of the activated partial thromboplastin time waveform. Clin Appl Thromb Hemost. 2018;24:764-70. DOI: 10.1177/1076029617724230, PMID: 28884611

14 Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia: impact of fac- tor and non‐factor replacement therapy on coagulation assays. J Thromb Haemost. 2020;18:1242-55. DOI: 10.1111/jth.14784, PMID: 32115865

15 Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors. Br J Haematol. 2020;190:727-35. DOI: 10.1111/bjh.16574, PMID: 32162680

16 Solano C, Zerafa P, Bird R. A study of atypical APTT deriva- tive curves on the ACL TOP coagulation analyser. Int J Lab Hematol. 2011;33:67-78. DOI: 10.1111/j.1751-553X.2010.01248. x, PMID: 20649909

17 Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors. Br J Haematol. 2020;190:727-35. DOI: 10.1111/bjh.16574, PMID: 32162680

18 Hatayama Y, Motokura T, Hosoda Y, Suzuki S, Namba H, Kato K, et al. Regression analysis to estimate the factor VIII activity of patients with hemophilia A without inhibitor who received emicizumab therapy. Clin Appl Thromb Hemost. 2022;28. DOI: 10.1177/10760296221082992, PMID: 35225012

19 Tan CW, Wong WH, Cheen MHH, Chu YMH, Lim SS, Ng LCK, et al. Assessment of aPTT-based clot waveform analy- sis for the detection of haemostatic changes in different types of infections. Sci Rep. 2020;10:14186. DOI: 10.1038/s41598- 020-71063-1, PMID: 32843693

20 Shimura T, Kurano M, Kanno Y, Ikeda M, Okamoto K, Jubishi D, et al. Clot waveform of APTT has abnormal pat- terns in subjects with COVID-19. Sci Rep. 2021;11:5190. DOI: 10.1038/s41598-021-84776-8, PMID: 33664450

21 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation param- eters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7. DOI: 10.1111/jth.14768, PMID: 32073213

参考文献をもっと見る